A new trading day began on Tuesday, with Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) stock price up 14.91% from the previous day of trading, before settling in for the closing price of $1.14. BCLI’s price has ranged from $0.72 to $6.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 32.00% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 30.74%. With a float of $7.64 million, this company’s outstanding shares have now reached $7.91 million.
In an organization with 27 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Brainstorm Cell Therapeutics, Inc (BCLI) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Brainstorm Cell Therapeutics, Inc is 22.32%, while institutional ownership is 10.40%. The most recent insider transaction that took place on Oct 01 ’24, was worth 6,292. In this transaction President & CEO of this company bought 1,836 shares at a rate of $3.43, taking the stock ownership to the 80,960 shares. Before that another transaction happened on Sep 30 ’24, when Company’s President & CEO bought 22,000 for $0.23, making the entire transaction worth $5,016. This insider now owns 1,186,865 shares in total.
Brainstorm Cell Therapeutics, Inc (BCLI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 30.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.48% during the next five years compared to 32.00% growth over the previous five years of trading.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Trading Performance Indicators
Here are Brainstorm Cell Therapeutics, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.98, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Brainstorm Cell Therapeutics, Inc (BCLI)
Let’s dig in a bit further. During the last 5-days, its volume was 0.58 million. That was inferior than the volume of 0.71 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.69%.
During the past 100 days, Brainstorm Cell Therapeutics, Inc’s (BCLI) raw stochastic average was set at 48.78%, which indicates a significant decrease from 96.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0914 in the past 14 days, which was lower than the 0.1190 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1736, while its 200-day Moving Average is $1.6593. However, in the short run, Brainstorm Cell Therapeutics, Inc’s stock first resistance to watch stands at $1.3700. Second resistance stands at $1.4300. The third major resistance level sits at $1.5400. If the price goes on to break the first support level at $1.2000, it is likely to go to the next support level at $1.0900. The third support level lies at $1.0300 if the price breaches the second support level.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Key Stats
With a market capitalization of 12.89 million, the company has a total of 9,839K Shares Outstanding. Currently, annual sales are 0 K while annual income is -11,620 K. The company’s previous quarter sales were 0 K while its latest quarter income was -2,860 K.
